1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Non-Small Cell Lung Cancer: KOL Insight

  • July 2015
  • Firstword Pharma
Report ID: 3153884

Summary

Table of Contents




Non-Small Cell Lung Cancer: KOL Insight offers detailed expert opinion on the continuing evolution of the treatment paradigm for EGFR/ALK positive and negative NSCLC, and the potential for targeting KRAS-mutation positive disease.

The treatment of advanced NSCLC has seen substantial advances in the past decade and this progress is set to continue, propelled by the development of checkpoint inhibitors and new targeted therapies. The second-line space is set to undergo a paradigm shift driven by the emergence of the PD-1 and PD-L1 inhibitors as well as new targeted agents. In the longer term the first-line setting will diversify as new products, including checkpoint inhibitors, vie for approval in this lucrative space.

Non-Small Cell Lung Cancer: KOL Insight presents a comprehensive qualitative review of targeted therapies in the market for advanced NSCLC with an emphasis on current and future treatment pathways.







Research Objectives


Which drugs constitute the first- and subsequent-line treatments of choice for patients in the following segments: EGFRm+, ALK translocation positive and EGFR mutation/ALK translocation negative? Which product attributes contribute to this preference?
How BMS’s Opdivo, Astellas’/Roche’s Tarceva, AstraZeneca’s Iressa, Boehringer Ingelheim’s Gilotrif and Vargatef, Pfizer’s Xalkori, Novartis’ Zykadia, Roche’s Avastin and Eli Lilly’s Cyramza are perceived by the medical community in terms of efficacy, tolerability, ease of administration, and other product attributes, and how they compare with other current and pipeline treatment options.
Which recently completed or ongoing clinical trials (e.g. CheckMate-057, CheckMate-026, CheckMate-227, KEYNOTE-021, OAK, PACIFIC, LUX-Lung 7, AURA3, TIGER-1, ALEX, AvaALL, SELECT-1 and HER3-Lung) have the greatest potential to impact prescribing trends, and how will the results impact the future treatment of NSCLC.
What do pipeline targeted therapies for NSCLC need to show in order to become the treatment of choice in a specific patient segment and line of therapy and is it likely the product will meet these requirements?
How the use of each current and pipeline targeted NSCLC product will change in the future in terms of patient segment, line of therapy and preference.
What pipeline products for NSCLC will need to show in terms of efficacy and tolerability endpoints to compete effectively, and what the likelihood is that the pipeline products will achieve those endpoints.
Which pipeline products are the most promising and how they will impact current players in the market (e.g. Merck & Co.’s Keytruda, Roche’s atezolizumab and alectinib, AstraZeneca’s durvalumab and mereletinib, Celgene’s/ Clovis’ rociletinib, BMS’s Yervoy, Array’s/AstraZeneca’s selumetinib and AbbVie’s veliparib).
How the treatment landscape for NSCLC will evolve in the future for each patient segment and line of therapy.



Key Opinion Leaders

KOLs from North America

Paul Bunn, Distinguished Professor, Division of Medical Oncology, University of Colorado Edward Garon, Associate Professor, Division of Hematology and Oncology, David Geffen School of Medicine, UCLA, Los Angeles, California
Giuseppe Giaccone, Associate Director for Clinical Research, Lombardi Comprehensive Cancer Center (LCCC) at Georgetown University, Washington, DC
Leora Horn, Assistant Professor of Medicine (Haematology/Oncology) and Clinical Director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center, Tennessee
Joan Shiller, Deputy Director of the Simmons Comprehensive Cancer Center and Division Director of Hematology/Oncology, University of Texas-Southwestern Medical Center, Texas
Mark Socinski, Professor of Medicine and Thoracic Surgery, University of Pittsburgh School of Medicine, Pennsylvania

KOLs from Europe

Ahmed Awada, Professor and Head of the Medical Oncology Clinic, Jules Bordet Institute, Brussels & Free Universities, Brussels, Belgium
Federico Cappuzzo, Professor and Director of Medical Oncology, Ospedale Civile di Livorno, Istituto Toscano Tumori-Ospedale Civile, Livorno, Italy
Solange Peters, Head of Thoracic Malignancies Program, Department of Oncology, University of Lausanne, Switzerland
David Planchard, Associate Professor, Department of Medical Oncology (Thoracic Oncology Group), Gustave-Roussy, France
Nick Thatcher, previously held the post of Professor of Medical Oncology at the Christie Hospital NHS Trust in Manchester, England
Anonymous KOL, Germany



Update Bulletins Offer Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.



Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, June 2015.
You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Ulcerative Colitis Market and Forecast Analysis

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Ulcerative colitis is a chronic inflammatory bowel disease that is characterized by inappropriate diffuse inflammation of the rectal and colonic mucosa, which occurs in the innermost laye ...

Crohn’s Disease Market and Forecast Analysis

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Crohn’s disease involves inflammation of the gastrointestinal (GI) tract and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of ...

OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • February 2017
  • by GlobalData

OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025 Summary Immune Thrombocytopenia (ITP) is an autoimmune-related bleeding disorder characterized by a low platelet ...

Hnscc: Kol Insight - 2017

March 2017 $ 8355

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.